Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Plu-Bureau

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
La Revue Du Praticien|December 15, 1993
[Treatment of menopause and cancer of the breast: epidemiological aspects]G Plu-Bureau
Therapie|September 29, 1999
[Cardiovascular risk and hormone replacement therapy in menopause]G Plu-Bureau
La Revue Du Praticien|December 1, 1995
[Oral contraception and risk of cancer. Epidemiological aspects of breast and gynecological cancers]G Plu-Bureau
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|May 11, 2000
[Hormone replacement therapy after breast cancer]G Plu-Bureau
Annals of the New York Academy of Sciences|September 16, 2010
Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy?A Gompel, G Plu-Bureau
Climacteric : the Journal of the International Menopause Society|June 2, 2018
Progesterone, progestins and the breast in menopause treatmentA Gompel, G Plu-Bureau
Archives Des Maladies Du Coeur Et Des Vaisseaux|February 1, 1993
[Quantitative evaluation of the cardiovascular risk associated with hormone substitution therapy during menopause]P Y Scarabin, G Plu-Bureau
Contraception, Fertilite, Sexualite (1992)|March 1, 1995
[Women at high risk for breast cancer: can we define a group of women in France who could participate in a prevention trial?]M G Lê, G Plu-Bureau
Gynecologie, Obstetrique, Fertilite & Senologie|March 24, 2021
[Menopausal hormone therapy an cardiovascular risk. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines]G Plu-Bureau, C Mounier-Vehier
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|November 4, 2015
[Post-partum contraception: Guidelines for clinical practice]B Raccah-Tebeka, G Plu-Bureau
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
La Revue Du Praticien|December 15, 1993
[Treatment of menopause and cancer of the breast: epidemiological aspects]G Plu-Bureau
Therapie|September 29, 1999
[Cardiovascular risk and hormone replacement therapy in menopause]G Plu-Bureau
La Revue Du Praticien|December 1, 1995
[Oral contraception and risk of cancer. Epidemiological aspects of breast and gynecological cancers]G Plu-Bureau
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|May 11, 2000
[Hormone replacement therapy after breast cancer]G Plu-Bureau
Annals of the New York Academy of Sciences|September 16, 2010
Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy?A Gompel, G Plu-Bureau
Climacteric : the Journal of the International Menopause Society|June 2, 2018
Progesterone, progestins and the breast in menopause treatmentA Gompel, G Plu-Bureau
Archives Des Maladies Du Coeur Et Des Vaisseaux|February 1, 1993
[Quantitative evaluation of the cardiovascular risk associated with hormone substitution therapy during menopause]P Y Scarabin, G Plu-Bureau
Contraception, Fertilite, Sexualite (1992)|March 1, 1995
[Women at high risk for breast cancer: can we define a group of women in France who could participate in a prevention trial?]M G Lê, G Plu-Bureau
Gynecologie, Obstetrique, Fertilite & Senologie|March 24, 2021
[Menopausal hormone therapy an cardiovascular risk. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines]G Plu-Bureau, C Mounier-Vehier
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|November 4, 2015
[Post-partum contraception: Guidelines for clinical practice]B Raccah-Tebeka, G Plu-Bureau
Pageof 7